Abstract: The present disclosure provides a method for noninvasively diagnosing and staging a progressive chronic lung disease characterized by disease related lung dysfunction by deriving from a biological sample from a subject a purified enriched population of exosomes in the biological sample, wherein dysregulated expression of the two or more microRNAs, compared to a healthy control, comprises a signature of a fibrotic lung disease; and medically managing the diagnosed fibrotic lung disease as early as possible in the course of progression of the disease to reduce or slow its progression. The method may identify interstitial pulmonary fibrosis (IPF) at a stage before standard procedures (e.g., Ashcroft scoring and histology) demonstrate changes consistent with lung fibrosis.

Abstract: The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.

Abstract: The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.

Abstract: The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides a composition containing a purified and enriched population of potent exosomes derived from extracellular vesicles derived from mesenchymal stem cells (MSCs), a method for diagnosing a human subject aged over 50 years with an age-related chronic disease characterized by disease related dysfunction and optimally treating the subject, and a method for reprogramming a donated organ or tissue comprising a fibrotic disposition including treating the donated organ or tissue with a composition comprising purified enriched population of potent exosomes derived from extracellular vesicles derived from MSCs of a normal healthy subject.

Abstract: The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.

Abstract: The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.